Kindred Biosciences (KIN)

9.25  +0.01 (+0.11%)

After market: 9.26 +0.01 (+0.11%)

Fundamental Rating

2

Taking everything into account, KIN scores 2 out of 10 in our fundamental rating. KIN was compared to 588 industry peers in the Biotechnology industry. The financial health of KIN is average, but there are quite some concerns on its profitability. KIN does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

KIN had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -38.53%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -500.9%
PM (TTM) -529.26%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

There is no outstanding debt for KIN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

KIN has an Altman-Z score of 4.83. This indicates that KIN is financially healthy and has little risk of bankruptcy at the moment.
KIN has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 4.83
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 7.02 indicates that KIN has no problem at all paying its short term obligations.
KIN has a Quick Ratio of 7.02. This indicates that KIN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 7.02
Quick Ratio 7.02

3

3. Growth

3.1 Past

The earnings per share for KIN have decreased strongly by -53.73% in the last year.
KIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -81.43%.
EPS 1Y (TTM)-53.73%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-130.77%
Revenue 1Y (TTM)-81.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-91.06%

3.2 Future

The Earnings Per Share is expected to grow by 12.40% on average over the next years. This is quite good.
KIN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.46% yearly.
EPS Next Y-51.22%
EPS Next 2Y36%
EPS Next 3Y15.8%
EPS Next 5Y12.4%
Revenue Next Year-49.68%
Revenue Next 2Y-1.59%
Revenue Next 3Y3.21%
Revenue Next 5Y20.46%

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

KIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.71

4.3 Compensation for Growth

A more expensive valuation may be justified as KIN's earnings are expected to grow with 15.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36%
EPS Next 3Y15.8%

0

5. Dividend

5.1 Amount

No dividends for KIN!.
Industry RankSector Rank
Dividend Yield N/A

Kindred Biosciences

NASDAQ:KIN (8/27/2021, 7:19:13 PM)

After market: 9.26 +0.01 (+0.11%)

9.25

+0.01 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap420.52M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.53%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -500.9%
PM (TTM) -529.26%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.02
Quick Ratio 7.02
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-53.73%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-51.22%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-81.43%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y